Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EPR Properties (EPR) vs Pfizer Inc (PFE) Price & Performance

EPR PropertiesTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

EPR Properties vs Pfizer Inc — how do they compare? EPR Properties trades at $62.12 (market cap $4.60B), while Pfizer Inc trades at $25.09 (market cap $141.46B). The key difference: Pfizer Inc is far larger — about 30.8× EPR Properties's market cap, and Pfizer Inc pays the higher dividend (6.93%). Which is the better fit depends on your goals.

EPRPFE
Market Cap
$4.60B$141.46B
Sector
Real EstateHealth
52-Week High
$60.81$28.56
52-Week Low
$48.71$23.29
Enterprise Value
$7.66B$192.12B
Dividend Yield
6.19%6.93%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EPR Properties

EPR Properties trades at $61.76, up 3.73% today, with a bullish technical signal from moving averages and recent breakout above key levels. The REIT shows strong profitability with 39.93% net income margin and consistent dividend payments, though Q1 2026 EPS slightly missed expectations. Recent news highlights monthly dividend declarations and a $315 million Six Flags acquisition diversifying its experiential portfolio.

Outlook remains positive with analyst consensus target of $63.25 offering modest upside, supported by 99% occupancy and stable cash flows. Risks include economic sensitivity of entertainment assets and potential interest rate impacts on REIT valuations. The stock presents a balance of income and growth for investors seeking REIT exposure.

Pfizer Inc

Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.

Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.

Returns comparison

Trailing returns across standard periods

About EPR Properties

EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.

Read more on EPR

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE